Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation

Allogeneic stem cell transplantation (allo-SCT) is the only curative treatment option for many hematological diseases, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Outcomes of allo-SCT have improved with better supportive care, reduced intensity conditioning regimens, and use of alternative stem cell donor sources. [1] However, relapsed disease after allo-SCT remains a major cause of treatment failure, occurring in approximately 40% of AML cases, most of which occur within the first year.

Source: Biology of Blood and Marrow Transplantation - January 31, 2020 Category: Hematology Authors: Amy Y. Wang, Justin Kline, Wendy Stock, Satyajit Kosuri, Andrew Artz, Richard A. Larson, Peter A. Riedell, Michael Bishop, Hongtao Liu Source Type: research